Development of a Mouse Glioblastoma Orthotopic Model Using the GLi-261 Cell Line

• Main Authors: A. A. Borzov, A. A. Оvsepyan, E. I. Katorkina, E. O. Anisimova, M. V. Lykov
• Format: Article
• Language: Russian
• Published: Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2019-12-01
• Series: Биопрепараты: Профилактика, диагностика, лечение
• Subjects: glioblastoma; stereotaxy; magnetic resonance imaging; temozolomide; orthotopic model
• Online Access: https://www.biopreparations.ru/jour/article/view/252
• ISSN: 2221-996X; 2619-1156

Glioblastoma is the most common and most aggressive type of brain tumor, with an almost 100 % mortality rate over 5 years. The search for new effective approaches to the treatment of this disease requires the development of adequate experimental models. Objective: to develop and put into practice an orthotopic model of mouse glioblastoma. Materials and methods: GLi-261 mouse glioma cells were orthotopically inoculated into the putamen of C57Bl/6 mice brain. Tumor dynamics was investigated by Preclinical MRI System 7.0T/17cm (Flexiscan) highfield magnetic resonance imager (MR Solutions, UK). Temcital® (temozolomide) was used as a positive control in the treatment of experimental glioblastoma. The neurological status of animals in the course of tumour development was assessed by specific tests. Results: a GLi-261 cell-based mouse glioblastoma orthotopic model was developed using stereotactic equipment for accurate inoculation of tumour cells, magnetic resonance imaging for non-invasive determination of tumour volume and dynamics, and special tests for determination of the neurological status of the biological test systems. This model was used to demonstrate the effectiveness of temozolomide (the «gold standard» for glioblastoma treatment). Conclusions: this model has been introduced into practice at the IBC Generium, LLC, and can be used as an in vivo test system for preclinical evaluation of efficacy of new antitumour drugs being developed, as well as brain cancer treatment regimens using combination therapy.